Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
01 2021
Historique:
received: 30 06 2020
revised: 13 08 2020
accepted: 19 08 2020
pubmed: 31 8 2020
medline: 15 4 2021
entrez: 31 8 2020
Statut: ppublish

Résumé

To determine the outcomes of oral cavity squamous cell cancer (OSCC) patients treated with non-surgical approach i.e. definitive intensity-modulated radiation therapy (IMRT). All OSCC patients treated radically with IMRT (without primary surgery) between 2005-2014 were reviewed in a prospectively collected database. OSCC patients treated with definitive RT received concurrent chemotherapy except for early stage patients or those who declined or were unfit for chemotherapy. The 5-year local, and regional, distant control rates, disease-free, overall, and cancer-specific survival, and late toxicity were analyzed. Among 1316 OSCC patients treated with curative-intent; 108 patients (8%) received non-operative management due to: medical inoperability (n = 14, 13%), surgical unresectability (n = 8, 7%), patient declined surgery (n = 15, 14%), attempted preservation of oral structure/function in view of required extensive surgery (n = 53, 49%) or extensive oropharyngeal involvement (n = 18, 17%). Sixty-eight (63%) were cT3-4, 38 (35%) were cN2-3, and 38 (35%) received concurrent chemotherapy. With a median follow-up of 52 months, the 5-year local, regional, distant control rate, disease-free, overall, and cancer-specific survival were 78%, 92%, 90%, 42%, 50%, and 76% respectively. Patients with cN2-3 had higher rate of 5-year distant metastasis (24% vs 3%, p = 0.001), with detrimental impact on DFS (p = 0.03) and OS (p < 0.02) on multivariable analysis. Grade ≥ 3 late toxicity was reported in 9% of patients (most common: grade 3 osteoradionecrosis in 6%). Non-operative management of OSCC resulted in a meaningful rate of locoregional control, and could be an alternative curative approach when primary surgery would be declined, unsuitable or unacceptably delayed.

Identifiants

pubmed: 32861702
pii: S0167-8140(20)30731-3
doi: 10.1016/j.radonc.2020.08.013
pmc: PMC7453211
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-75

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Ali Hosni (A)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada. Electronic address: Ali.Hosni@rmp.uhn.on.ca.

Kevin Chiu (K)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Shao Hui Huang (SH)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Wei Xu (W)

Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Canada.

Jingyue Huang (J)

Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Canada.

Andrew Bayley (A)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Scott V Bratman (SV)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

John Cho (J)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Meredith Giuliani (M)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

John Kim (J)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Brian O'Sullivan (B)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Jolie Ringash (J)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

John Waldron (J)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Anna Spreafico (A)

Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

John R de Almeida (JR)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Eric Monteiro (E)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Ian Witterick (I)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Douglas B Chepeha (DB)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

R W Gilbert (RW)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Jonathan C Irish (JC)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

David P Goldstein (DP)

Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.

Andrew Hope (A)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada. Electronic address: Andrew.Hope@rmp.uhn.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH